Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 39Breast 4Tumor-Agnostic 2Thoracic 2Gastrointestinal 2Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Salivary Cancer 1

Interventions

pembrolizumab 66Cisplatin 55Radiotherapy, Intensity-Modulated 28Carboplatin 27Nivolumab 26Paclitaxel 21Magnetic Resonance Spectroscopy 21Radiotherapy 20Cetuximab 16Specimen Handling 15Docetaxel 15Radiation 14Gemcitabine 13Fluorouracil 12Biopsy 12durvalumab 11Platinum 11Taxes 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Surveys and Questionnaires 9Capecitabine 9trametinib 8tislelizumab 6lenvatinib 6dabrafenib 6cemiplimab 6atezolizumab 6Radiosurgery 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × enzalutamide × Head & Neck × Clear all
NCT02749903 2026-02-11

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
46 enrolled 11 charts
Head & Neck

Salivary Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡